Heterogeneity of Mesenchymal Markers Expression—Molecular Profiles of Cancer Cells Disseminated by Lymphatic and Hematogenous Routes in Breast Cancer

Cancers

Volumn 5, Issue 4, 2013, Pages 1485-1503

  Markiewicz, Aleksandra ^a,b   Książkiewicz, Magdalena ^a   Seroczyńska, Barbara ^a   Skokowski, Jarosław ^a   Szade, Jolanta ^a   Wełnicka Jaśkiewicz, Marzena ^a   Zaczek, Anna J ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Breast cancer; Cancer dissemination; Circulating tumor cells; Epithelial mesenchymal transition; Lymph node metastasis; Metastasis

Indexed keywords

EID: 84899456668     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers5041485     Document Type: Article

References (66)

1. Carter, C.L.; Allen, C.; Henson, D.E. Relation of tumor size, lymph node status, and survival in
2. 24,740 breast cancer cases. Cancer 1989, 63, 181-187.
3. Fisher, B.; Anderson, S.; Bryant, J.; Margolese, R.G.; Deutsch, M.; Fisher, E.R.; Jeong, J.-H.; Wolmark, N. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N. Engl. J. Med. 2002, 347, 1233-1241.
4. Quiet, C.A.; Ferguson, D.J.; Weichselbaum, R.R.; Hellman, S. Natural history of node-negative breast cancer: A study of 826 patients with long-term follow-up. J. Clin. Oncol. 1995, 13, 1144-1151.
5. Group, E.B.C.T.C. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005, 365, 1687-1717.
6. Braun, S.; Vogl, F.D.; Naume, B.; Janni, W.; Osborne, M.P.; Coombes, R.C.; Schlimok, G.; Diel, I.J.; Gerber, B.; Gebauer, G.; et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N. Engl. J. Med. 2005, 353, 793-802.
7. Zhang, L.; Riethdorf, S.; Wu, G.; Wang, T.; Yang, K.; Peng, G.; Liu, J.; Pantel, K. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin. Cancer Res. 2012, 18, 5701-5710.
8. Lucci, A.; Hall, C.S.; Lodhi, A.K.; Bhattacharyya, A.; Anderson, A.E.; Xiao, L.; Bedrosian, I.; Kuerer, H.M.; Krishnamurthy, S. Circulating tumour cells in non-metastatic breast cancer: A prospective study. Lancet Oncol. 2012, 13, 688-695.
9. Bidard, F.C.; Mathiot, C.; Delaloge, S.; Brain, E.; Giachetti, S.; de Cremoux, P.; Marty, M.; Pierga, J.Y. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann. Oncol. 2010, 21, 729-733.
10. Cristofanilli, M.; Budd, G.T.; Ellis, M.J.; Stopeck, A.; Matera, J.; Miller, M.C.; Reuben, J.M.; Doyle, G.V.; Allard, W.J.; Terstappen, L.W.M.M.; et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 2004, 351, 781-791.
11. Giuliano, M.; Giordano, A.; Jackson, S.; Hess, K.R.; de Giorgi, U.; Mego, M.; Handy, B.C.;Ueno, N.T.; Alvarez, R.H.; de Laurentiis, M.; et al. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res. 2011, 13, doi:10.1186/bcr2907.
12. Pierga, J.-Y.; Hajage, D.; Bachelot, T.; Delaloge, S.; Brain, E.; Campone, M.; Diéras, V.; Rolland, E.; Mignot, L.; Mathiot, C.; et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann. Oncol. 2012, 23, 618-624.
13. Xenidis, N.; Ignatiadis, M.; Apostolaki, S.; Perraki, M.; Kalbakis, K.; Agelaki, S.; Stathopoulos, E.N.; Chlouverakis, G.; Lianidou, E.; Kakolyris, S.; et al. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J. Clin. Oncol. 2009, 27, 2177-2184.
14. Stathopoulou, A.; Vlachonikolis, I.; Mavroudis, D.; Perraki, M.; Kouroussis, C.; Apostolaki, S.; Malamos, N.; Kakolyris, S.; Kotsakis, A.; Xenidis, N.; et al. Molecular detection of cytokeratin-19- positive cells in the peripheral blood of patients with operable breast cancer: Evaluation of their prognostic significance. J. Clin. Oncol. 2002, 20, 3404-3412.
15. Zhao, S.; Liu, Y.; Zhang, Q.; Li, H.; Zhang, M.; Ma, W.; Zhao, W.; Wang, J.; Yang, M. The prognostic role of circulating tumor cells (CTCs) detected by RT-PCR in breast cancer: A meta-analysis of published literature. Breast Cancer Res. Treat. 2011, 130, 809-816.
16. Paget, S. The distribution of secondary growths in cancer of the breast. Lancet 1889, 133, 571-573.
17. Mani, S.A.; Guo, W.; Liao, M.J.; Eaton, E.N.; Ayyanan, A.; Zhou, A.Y.; Brooks, M.; Reinhard, F.; Zhang, C.C.; Shipitsin, M.; et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133, 704-715.
18. Polyak, K.; Weinberg, R.A. Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat. Rev. Cancer 2009, 9, 265-273.
19. Thiery, J.P.; Sleeman, J.P. Complex networks orchestrate epithelial-mesenchymal transitions. Nat. Rev. Mol. Cell Biol. 2006, 7, 131-142.
20. Thiery, J.P.; Acloque, H.; Huang, R.Y.; Nieto, M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139, 871-890.
21. Książkiewicz, M.; Markiewicz, A.; Żaczek, A.J. Epithelial-mesenchymal transition: A hallmark in metastasis formation linking circulating tumor cells and cancer stem cells. Pathobiology 2012, 79, 195-208.
22. Van Nes, J.; de Kruijf, E.; Putter, H.; Faratian, D.; Munro, A.; Campbell, F.; Smit, V.; Liefers, G.-J.; Kuppen, P.; van de Velde, C.; et al. Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor-positive early breast cancer patients. Breast Cancer Res. Treat. 2012, 133, 49-59.
23. Elloul, S.; Bukholt Elstrand, M.; Nesland, J.M.; Tropé, C.G.; Kvalheim, G.; Goldberg, I.; Reich, R.; Davidson, B. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer 2005, 103, 1631-1643.
24. Martin, T.; Goyal, A.; Watkins, G.; Jiang, W. Expression of the Transcription Factors Snail, Slug, and Twist and Their Clinical Significance in Human Breast Cancer. Ann. Surg. Oncol. 2005, 12, 488-496.
25. Markiewicz, A.; Ahrends, T.; Wenicka-Jakiewicz, M.; Seroczyska, B.; Skokowski, J.; Jakiewicz, J.; Szade, J.; Biernat, W.; Aczek, A. Expression of epithelial to mesenchymal transition-related markers in lymph node metastases as a surrogate for primary tumor metastatic potential in breast cancer. J. Transl. Med. 2012, 10, doi:10.1186/1479-5876-10-226.
26. Aktas, B.; Tewes, M.; Fehm, T.; Hauch, S.; Kimmig, R.; Kasimir-Bauer, S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res. 2009, 11, doi:10.1186/bcr2333.
27. Kallergi, G.; Papadaki, M.; Politaki, E.; Mavroudis, D.; Georgoulias, V.; Agelaki, S. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Res. 2011, 13, doi:10.1186/bcr2896.
28. Lianidou, E.S.; Mavroudis, D.; Georgoulias, V. Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer. Br. J. Cancer 2013, 108, 2426-2432.
29. Kasimir-Bauer, S.; Hoffmann, O.; Wallwiener, D.; Kimmig, R.; Fehm, T. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res. 2012, 14, doi:10.1186/bcr3099.
30. Barriere, G.; Riouallon, A.; Renaudie, J.; Tartary, M.; Rigaud, M. Mesenchymal and stemness circulating tumor cells in early breast cancer diagnosis. BMC Cancer 2012, 12, doi:10.1186/1471-2407-12-114.
31. Yu, M.; Bardia, A.; Wittner, B.S.; Stott, S.L.; Smas, M.E.; Ting, D.T.; Isakoff, S.J.; Ciciliano, J.C.; Wells, M.N.; Shah, A.M.; et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013, 339, 580-584.
32. Gradilone, A.; Raimondi, C.; Nicolazzo, C.; Petracca, A.; Gandini, O.; Vincenzi, B.; Naso, G.; Aglianò, A.M.; Cortesi, E.; Gazzaniga, P. Circulating tumour cells lacking cytokeratin in breast cancer: The importance of being mesenchymal. J. Cell. Mol. Med. 2011, 15, 1066-1070.
33. Ignatiadis, M.; Kallergi, G.; Ntoulia, M.; Perraki, M.; Apostolaki, S.; Kafousi, M.; Chlouverakis, G.; Stathopoulos, E.; Lianidou, E.; Georgoulias, V.; et al. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin. Cancer Res. 2008, 14, 2593-2600.
34. Apostolaki, S.; Perraki, M.; Kallergi, G.; Kafousi, M.; Papadopoulos, S.; Kotsakis, A.; Pallis, A.; Xenidis, N.; Kalmanti, L.; Kalbakis, K.; et al. Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: Evaluation of their prognostic relevance. Breast Cancer Res. Treat. 2009, 117, 525-534.
35. Riethdorf, S.; Muller, V.; Zhang, L.; Rau, T.; Loibl, S.; Komor, M.; Roller, M.; Huober, J.; Fehm, T.; Schrader, I.; et al. Detection and HER2 expression of circulating tumor cells: Prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin. Cancer Res. 2010, 16, 2634-2645.
36. Mego, M.; Mani, S.; Lee, B.; Li1, C.; Evans, K.; Cohen, E.; Gaol, H.; Jackson, S.; Giordano, A.; Hortobagyi, G.; et al. Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy. Int. J. Cancer 2012, 130, 808-816.
37. Rack, B.K.; Schindlbeck, C.; Andergassen, U.; Schneeweiss, A.; Zwingers, T.; Lichtenegger, W.; Beckmann, M.; Sommer, H.L.; Pantel, K.; Janni, W.; et al. Use of circulating tumor cells (CTC) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict risk for relapse: The SUCCESS trial. J. Clin. Oncol. 2010, 28, No. 15_suppl 1003.
38. Leong, S.P.; Cady, B.; Jablons, D.M.; Garcia-Aguilar, J.; Reintgen, D.; Jakub, J.; Pendas, S.; Duhaime, L.; Cassell, R.; Gardner, M.; et al. Clinical patterns of metastasis. Cancer Metastasis Rev. 2006, 25, 221-232.
39. Disibio, G.; French, S.W. Metastatic patterns of cancers: Results from a large autopsy study. Arch. Pathol. Lab. Med. 2008, 132, 931-939.
40. Cao, Y. Opinion: Emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis. Nat. Rev. Cancer 2005, 5, 735-743.
41. Klevesath, M.B.; Pantel, K.; Agbaje, O.; Provenzano, E.; Wishart, G.C.; Gough, P.; Pinder, S.E.; Duffy, S.; Purushotham, A.D. Patterns of metastatic spread in early breast cancer. Breast 2013, 22, 449-454.
42. Wong, S.Y.; Hynes, R.O. Lymphatic or hematogenous dissemination: How does a metastatic tumor cell decide? Cell Cycle 2006, 5, 812-817.
43. Alitalo, K.; Carmeliet, P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 2002, 1, 219-227.
44. Irjala, H.; Alanen, K.; Grenman, R.; Heikkila, P.; Joensuu, H.; Jalkanen, S. Mannose receptor (MR) and common lymphatic endothelial and vascular endothelial receptor (CLEVER)-1 direct the binding of cancer cells to the lymph vessel endothelium. Cancer Res. 2003, 63, 4671-4676.
45. Jain, R.K.; Munn, L.L.; Fukumura, D. Dissecting tumour pathophysiology using intravital microscopy. Nat. Rev. Cancer 2002, 2, 266-276.
46. Byers, S.W.; Sommers, C.L.; Hoxter, B.; Mercurio, A.M.; Tozeren, A. Role of E-cadherin in the response of tumor cell aggregates to lymphatic, venous and arterial flow: Measurement of cell-cell adhesion strength. J. Cell Sci. 1995, 108, 2053-2064.
47. Giampieri, S.; Manning, C.; Hooper, S.; Jones, L.; Hill, C.S.; Sahai, E. Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat. Cell Biol. 2009, 11, 1287-1296.
48. Marinari, E.; Mehonic, A.; Curran, S.; Gale, J.; Duke, T.; Baum, B. Live-cell delamination counterbalances epithelial growth to limit tissue overcrowding. Nature 2012, 484, 542-545.
49. Van der Auwera, I.; Peeters, D.; Benoy, I.H.; Elst, H.J.; van Laere, S.J.; Prove, A.; Maes, H.; Huget, P.; van Dam, P.; Vermeulen, P.B.; et al. Circulating tumour cell detection: A direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer. Br. J. Cancer 2010, 102, 276-284.
50. Strati, A.; Markou, A.; Parisi, C.; Politaki, E.; Mavroudis, D.; Georgoulias, V.; Lianidou, E. Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR. BMC Cancer 2011, 11, doi:10.1186/1471-2407-11-422.
51. Gorges, T.; Tinhofer, I.; Drosch, M.; Rose, L.; Zollner, T.; Krahn, T.; von Ahsen, O. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition. BMC Cancer 2012, 12, e178.
52. Xenidis, N.; Perraki, M.; Kafousi, M.; Apostolaki, S.; Bolonaki, I.; Stathopoulou, A.; Kalbakis, K.; Androulakis, N.; Kouroussis, C.; Pallis, T.; et al. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J. Clin. Oncol. 2006, 24, 3756-3762.
53. Xenidis, N.; Vlachonikolis, I.; Mavroudis, D.; Perraki, M.; Stathopoulou, A.; Malamos, N.; Kouroussis, C.; Kakolyris, S.; Apostolaki, S.; Vardakis, N.; et al. Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer. Ann. Oncol. 2003, 14, 849-855.
54. Strati, A.; Kasimir-Bauer, S.; Markou, A.; Parisi, C.; Lianidou, E.S. Comparison of three molecular assays for the detection and molecular characterization of circulating tumor cells in breast cancer. Breast Cancer Res. 2013, 15, doi:10.1186/bcr3395.
55. Joosse, S.A.; Hannemann, J.; Spotter, J.; Bauche, A.; Andreas, A.; Muller, V.; Pantel, K. Changes in keratin expression during metastatic progression of breast cancer: Impact on the detection of circulating tumor cells. Clin. Cancer Res. 2012, 18, 993-1003.
56. Molloy, T.J.; Devriese, L.A.; Helgason, H.H.; Bosma, A.J.; Hauptmann, M.; Voest, E.E.; Schellens, J.H.M.; van’t Veer, L.J. A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer. Br. J. Cancer 2011, 104, 1913-1919.
57. Chen, Y.; Zou, T.N.; Wu, Z.P.; Zhou, Y.C.; Gu, Y.L.; Liu, X.; Jin, C.G.; Wang, X.C. Detection of cytokeratin 19, human mammaglobin, and carcinoembryonic antigen-positive circulating tumor cells by three-marker reverse transcription-PCR assay and its relation to clinical outcome in early breast cancer. Int. J. Biol. Markers 2010, 25, 59-68.
58. Chong, M.H.; Zhao, Y.; Wang, J.; Zha, X.M.; Liu, X.A.; Ling, L.J.; Du, Q.; Wang, S. The dynamic change of circulating tumour cells in patients with operable breast cancer before and after chemotherapy based on a multimarker QPCR platform. Br. J. Cancer 2012, 106, 1605-1610.
59. Raimondi, C.; Gradilone, A.; Naso, G.; Vincenzi, B.; Petracca, A.; Nicolazzo, C.; Palazzo, A.; Saltarelli, R.; Spremberg, F.; Cortesi, E.; et al. Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res. Treat. 2011, 130, 449-455.
60. Wulfing, P.; Borchard, J.; Buerger, H.; Heidl, S.; Zanker, K.S.; Kiesel, L.; Brandt, B. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin. Cancer Res. 2006, 12, 1715-1720.
61. Pecot, C.V.; Bischoff, F.Z.; Mayer, J.A.; Wong, K.L.; Pham, T.; Bottsford-Miller, J.; Stone, R.L.; Lin, Y.G.; Jaladurgam, P.; Roh, J.W.; et al. A novel platform for detection of CK+ and CK−CTCs. Cancer Discov. 2011, 1, 580-586.
62. Żaczek, A.J.; Markiewicz, A.; Seroczyńska, B.; Skokowski, J.; Jaśkiewicz, J.; Pieńkowski, T.; Olszewski, W.P.; Szade, J.; Rhone, P.; Wełnicka-Jaśkiewicz, M.; et al. Prognostic Significance of TOP2A Gene Dosage in HER-2-Negative Breast Cancer. Oncologist 2012, 17, 1246-1255.
63. Goldhirsch, A.; Wood, W.C.; Coates, A.S.; Gelber, R.D.; Thürlimann, B.; Senn, H.-J.; members, P. Strategies for subtypes—Dealing with the diversity of breast cancer: Highlights of the St Gallen International expert consensus on the primary therapy of early breast cancer 2011. Ann. Oncol. 2011, 22, 1736-1747.
64. STATISTICA (data analysis software system), version 10. Statsoft, Inc.: Tulsa, OK, USA, 2011.
65. MedCalc Statistical Software, version 12.7.2. MedCalc Software bvba: Ostend, Belgium; 2013.
66. Landis, J.R.; Koch, G.G. The measurement of observer agreement for categorical data. Biometrics 1977, 33, 159-174.